SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
By recycling carbon dioxide into methanol, this science supports U.S. climate goals and helps reduce greenhouse gases.
SRI is spearheading a way for autonomous systems, such as self-driving vehicles and drones, to effectively operate in evolving and adversarial environments such as war zones.
The U.S. Department of Education issues a third five-year cooperative agreement to SRI to lead The DaSy Center.